Skip to content
Sign in
Artwork for OncoPharm
OncoPharm · May 7 · 11 min

Vepdegestrant

The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice. Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

0:00-11:35
Play in

transcript

No transcript — this publisher did not publish one.

show notes

The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice.

Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

more episodes

All episodes